Clinical Trials Logo

Clinical Trial Summary

Erythromycin and clindamycin are believed to have anti-inflammatory aspects. This study investigates the possible anti-inflammatory effects of erythromycin and clindamycin.


Clinical Trial Description

Convincing mechanistic reports on the immunomodulatory action of erythromycin and clindamycin are scarce, rarely based on experiments in freshly isolated human immune cells, and potentially contradicting. Moreover, direct immunomodulatory effects of both antibiotics have never been demonstrated in vivo. The Centre for Human Drug Research Biomarker lab has studied in depth the immunomodulatory actions of erythromycin and clindamycin in vitro. These in vitro experiments on primary human immune cells demonstrated that both erythromycin and clindamycin are able to modulate the immune response of peripheral blood mononuclear cells upon stimulation with different immune triggers such as lipopolysaccharide (LPS) and polyI:C. In this current study the in vitro work will be translated to an in vivo study where it will be made into an intradermal LPS skin challenge model in healthy volunteers. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03779360
Study type Interventional
Source Centre for Human Drug Research, Netherlands
Contact
Status Completed
Phase N/A
Start date October 12, 2018
Completion date February 23, 2019

See also
  Status Clinical Trial Phase
Completed NCT03066791 - Turmeric and Curcumin on Sebum Production N/A
Active, not recruiting NCT05913791 - Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema N/A
Completed NCT04308889 - Pro-Resolving Mediators in Acute Inflammation in Humans Early Phase 1
Completed NCT03183830 - Influence of Dietary Nitrate on Skin Inflammation Phase 1
Completed NCT04848194 - Pleiotropic Role of TRPV1 in Psoriasis Inflammation N/A
Active, not recruiting NCT05110313 - Effects of Tildrakizumab on Epigenetic Age Phase 4